title: Analysis of risk factors of surgical site infections in breast cancer.
abstract: BACKGROUND
  Adjuvant chemotherapy has become an important component of standard therapy for breast cancer. However, until now, there have been few reports on the surgical site infections (SSI) after breast cancer surgery, specially after adjuvant chemotherapy. To study the risk factors of SSI of breast cancer, we analyzed patients diagnosed with breast cancer and treated with surgery.
  
  
  METHODS
  Fifty-five patients diagnosed with breast cancer and received breast conserving or modified radical operations in our hospital during January 2008 to March 2008 were selected. Factors (patients' age, body mass index (BMI), diabetes mellitus, no or administered adjuvant chemotherapy, with or without onset of myelosuppression and the degree, surgical approaches, duration of operation, postoperative drainage duration and total drainage volume) associated with SSI were retrospectively reviewed and statistically analyzed by single factor analysis.
  
  
  RESULTS
  Five patients suffered SSI (5/55, 9.1%); nineteen receiving adjuvant chemotherapy experienced Grade III + myelosuppression, among which 4 had SSI; only 1 out of the remaining 36 patients without adjuvant chemotherapy had SSI. The difference between the two groups was significant (P = 0.043). The incidence of SSI in patients with post-operative drainage tube indwelling longer than 10 days was 5/21, whereas no SSI occurred in that less than 10 days (P = 0.009). In our study, there was no significant difference in other associated factors.
  
  
  CONCLUSIONS
  Concurrent Grade III + myelosuppression after adjuvant chemotherapy is an important risk factor of SSI in breast cancer and needs further study. No SSI was detected with indwelling time of post operative drainage less than 10 days.
authors.affiliation: Center of Breast Disease, Peking University First Hospital, Beijing 100034, China.
authors.forename: Yang-xu
authors.initials: YX
authors.lastname: Gao
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.forename: Jing-ming
authors.initials: JM
authors.lastname: Ye
authors.forename: Dong-min
authors.initials: DM
authors.lastname: Wang
authors.forename: Jian-xin
authors.initials: JX
authors.lastname: Zhao
authors.forename: Lan-bo
authors.initials: LB
authors.lastname: Zhang
authors.forename: Xue-ning
authors.initials: XN
authors.lastname: Duan
authors.forename: Yin-hua
authors.initials: YH
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000601:surgery*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013530:Surgical Wound Infection / Q000209:etiology*
chemical_list: D016179:Granulocyte Colony-Stimulating Factor